This new, sensitive, specific "sandwich"-type enzyme-linked immunosorbent assay (ELIsA) for quantifying Iipoprotein(a) [Lp(a)J in human serum and in ultracentrifugal lipoprotein fractions is based on use of a monoclonal antibody raised against apolipoprotein(a) as coating protein and a polyclonal antibody, raised against either apo B or against Lp(a) and conjugated with peroxidase, for detection of bound Lp(a). Mean intra-and interassay CVs for assay of 16 samples were 3.0% and 5.6%, respectively. Sample pretreatment with urea did not enhance Lp(a) immunoreactivity, and treatment with nonionic detergents decreased binding to the monoclonal antibody. Results correlated well (r = 0.99, n = 38) with those by radial immunodiffusion (RID). The ELISA assay, however, detects amounts corresponding to Lp(a) contents of 10 to 1000 mg/L in plasma samples diluted 1000-fold, compared with 100-500 mg/L for RID. For 92 normolipidemic subjects, the mean Lp(a) concentration was 120 (SD 130) mg/L. In patients undergoing coronary angiography, Lp(a) concentrations increased with the severityof the disease but were not correlated with either HDL cholesterol, triglycerides, apo A-I, or apo B, and only weakly with plasma cholesterol and apo A-Il. These two correlations were even weaker in normal subjects, and only the correlation with total cholesterol was valid. Lp(a), measured at birth and at seven days and six months, steadily increased with age. This assay is well suited for measuring Lp(a) in plasma and in lipoprotein fractions and also for screening programs evaluating this significant genetic risk factor for the development of atherosclerosis.
diet, lifestyle, or therapy with hydroxymethylglutaryl-CoA reductase (EC 1.1.1.88) inhibitors (6, 7) . The Lp(a) molecule consists of one molecule of apo B and one molecule of apo(a), linked by a disulfide bridge (8) . Because of its high homology to plasminogen (9), quantification of Lp(a) requires the use of either affinity-purified polyclonal antisera or, preferably, monoclonal antibodies that do not react with plasminogen.
Immunological assays for Lp(a) for radial immunodiffusion (RID) (10) , electroiminunoassay (11) , radioimmunoassay (12) , and ELISA (13) , with polyclonal antisera, have been reported, as has one ELISA assay with monoclonal antibody (14) .
We describe here a sensitive and rapid "sandwich"-type ELISA assay, in which a combination of a specific monoclonal antibody is used for coating and a stable polyclonal anti-ape B-peroxidase conjugate is used for detection. Although Lp(a) concentrations range from <5 to >1000 mg/L in the population, the ELISA assay provides both the sensitivity and the assay range required for measurements of Lp(a) in plasma samples and in lipoprotein fractions. After validating the assay by comparison with RID, we applied it to the characterization of Lp(a) concentrations and distribution in neonates and in adults.
MaterIals and Methods
Isolation of lipoproteins and production of antisera. The LDL were obtained by ultracentrifugal flotation of fresh plasma at densities between 1.03 and 1.05 kg/L (15) . Lp(a) was purified by ultracentrifugation of plasma from donors with high Lp(a) concentrations (>500 mgfL) at densities between 1.06 and 1.10 kgfL. It was further purified by gel filtration on columns of either Sepharose 6B or Superose FPLC ("Fast Protein Liquid Chromatography"; Pharmacia, Uppsala, Sweden) (13) . Only the first-eluting fraction, the one that contains pure Lp(a), was retained. Its purity was checked by gradient gel electrophoresis and by a sensitive ELISA for ape A-I and B. No contamination with either LDL or HDL was observed.
Apo(a) was obtained after reduction of the Lp(a) lipoprotein fraction in the presence of dithiothreitol, 0.5 mmoIJL, for 1 h at 23 #{176}C, followed by ultracentrifugation (16) . Apolipoproteins A-I and B, and their respective antisera, were prepared as previously described (17).
Rabbits were immunized by subcutaneous injection of 0.4 mg of Lp(a), dissolved in 0.5 mL of 5 mmol/L NH4HCO3 buffer and emulsified with an equal volume of Freund's complete adjuvant (Difco, Detroit, MI). Booster injections of 0.25 mg of Lp(a), in Freund's incomplete adjuvant, were given at three-week intervals until reasonable titers were obtained. Antisera were obtained by bleeding the animals 10 days after the last injection.
For the generation of monoclonal antibodies, spleen cells of Balb/c mice immunized with Lp(a) were fused according to standard procedures (16) . We obtained 14 stable clones, which we tested for specificity against LDL, plasminogen, and apo(a); they reacted only with apo(a) (16) . In our assay We verified the concentration of the Lp(a) standard by the classical Lowry procedure for protein and by measuring phenylalanine by HPLC (17) . We also compared the response of the primary standard with that of a calibrated serum from Immuno Gmbh, Vienna, Austria.
Three pooled sera from normolipidemic donors with low, medium, or high Lp(a) concentrations, respectively, were apportioned and stored at -20 #{176}C for use as secondary standards and controls (17). We prepared standard curves by plotting the absorbance at 490 nm as a function of the logarithm of the Lp(a) concentration and fitted them to an equation of Rodbard with three parameters (17). The specificity of the assay was controlled by checking its crossreactivity with LDL, ape A-I, albumin, and lipoprotein-free serum.
Subjects. Blood, collected from normal and hyperlipidemic subjects after they had fasted overnight, was treated with disodium EDTA (final concentration 1 g/L), aprotimn ("Trasylol"; Bayer, Leverkusen, F.R.G.; 104 kallikrein units/L), and sodium azide (0.2 gIL). The separated plasma obtained was stored at -20 #{176}C for no longer than three months before analysis.
The normal subjects had been recruited for the WHO-MONICA project, for monitoring coronary risk factors in the general population. Hyperlipidemic subjects were classified according to Fredrickson et al. (18) . Plasma was sampled from patients who were undergoing coronarography and who were classified as having one-, two-, or three-vessel disease on the basis of the angiogram. The familial history of coronary heart disease in these patients was also recorded. Plasma was also obtained from newborns at birth; seven, 30, and 90 days postpartum; and at age six to eight months.
Lp(a) distribution. Lipoproteins were separated from 0.5 mL of fresh plasma by isopycnic ultracentrifugation in a sodium chloride-sucrose gradient (19) . Ape A-I and B, and Lp(a) were quantified in all fractions by immunonephelometry (15, 20) and by our sandwich ELISA, respectively. Lipids were determined enzymatically (19) . Sample treatment. To investigate the influence of sample pretreatment with detergents or denaturants on the Lp(a) concentrations, we treated three plasma samples [Lp(a) concentrations of 347, 550, or 830 mg/LI by diluting them 1000-fold with buffer containing urea, 4 mol/L, Tween 20, 0.5 gIL, or Triton X-100, 0.10 g/L (final concentrations). We compared the Lp(a) concentrations measured after these various treatments.
Lp(a) quantification by RID. For this we used immunediffusion plates, reagents, and standards from Immuno Gmbh.
Results
Assay conditions and standardization.
The calibration curve obtained with fresh plasma samples paralleled that obtained when purified Lp(a) was used as a primary standard (Figure 1) . We investigated the specificity of the ELISA assay for Lp(a) by constructing standard curves with punfled ape A-I, human albumin, and lipeprotein-free serum as a source of plasminogen; LDL (d 1.03-1.05) as a source of ape B; and ape(a). As shown in Figure 1 , the specificity of the monoclonal antibody used for coating sufficed to keep the cross-reactivity of these antigens with the monospecific anti-ape B conjugate at 0.20% for ape(a), 0.02% for LDL and for plasminogen in the lipoprotein-free serum, and <0.01% for ape A-I and albumin.
Standard curves obtained with the two types of conjugates-polyclonal anti-ape B and anti Lp(a), both labeled with peroxidase-are shown in Figure 2 . The assay range is similar for both conjugates (2-50 ng) and the standard curves obtained with Immuno reference serum are quite comparable, as are the values determined for 25 samples. This suggests that both conjugates react with epitopes to ape(a) and ape B, respectively, both of which are equally accessible. We tested the influence of sample pretreatment on Lp(a) immunoreactivity either by exposing samples to denaturing agents (urea) before dilution or by adding detergents to the dilution buffer. Exposure to 4 mol/L urea had no significant effect on the immunoreactivity of Lp(a), whereas the nonionic detergents, Tween 20 and Triton X-100, decreased the Lp(a) immunoreactivity by 17% and 35%, respectively. The intraassay CV of the assay was greater (3% vs 9%) when the detergents were used. Deter- For samples with a lower concentration, a 500-to 1000-fold dilution is recommended. The standard curve was fitted to the three-parameter Rodbard equation by leastsquares analysis, and unknown concentrations were calculated from the fitted curve.
The pooled-plasma samples with low, intermediate, and high concentrations of Lp(a) were analyzed 10 times on the same day and on 12 separate days to calculate the assay precision. Mean intra-and interassay CVs were 3.0% and 5.6%, respectively.
Lp(a) concentrations in plasma. We determined the Lp(a) concentrations in plasma from 92 normolipidemic individuals and from 141 patients who were undergoing coronary angiography ( Table 1 ). The mean Lp(a) concentration was 120 (SD 130) mg/L for the normolipemic individuals by the proposed sandwich ELISA. We observed no significant sexrelated differences.
As summarized in Table 1 , the Lp(a) values in the coronarography patients increased with the severity of the lesions. We observed a significant difference between the patients with no vessel obstruction and the group with three-vessel disease, in agreement with previous reports (6). When we classified the same individuals according to their lipid values, we observed significantly increased Lp(a) concentrations in the group of Type 11A hyperlipoproteinemic subjects. However, 92% of this group consisted of patients with documented two-or three-vessel coronary artery disease, we could not clearly define the association of Lp(a) values with lipids within this group. Plasma Lp(a) concentrations ranged between 5 and 1500 mg/L in normolipemic and hyperlipemic individuals. They were not correlated with either HDL cholesterol, ape Al, ape B, or triglyceride concentrations.
We observed only a weak correlation with ape All and with plasma cholesterol.
We also measured Lp(a) in newborns, to compare the evolution of the Lp(a) profiles with those of LDL ape B in the same infants. As shown in Table 2 , the Lp(a) in plasma increased most between birth and seven days, as observed for ape B. However, Lp(a) increased up to six months, whereas the concentrations of the other apelipoproteins had stabilized after 30 days (19) . With this assay we could detect infants with high Lp(a) concentrations at birth, for whom we confirmed a hereditary pattern (21) .
Distribution of Lpa) in plasma. Utermann et al. (6) suggested a significant association between the Lp(a) concentration, its maximal density, and the size of the apo(a) glycoprotein. We therefore monitored the distribution of Lp(a) in five subjects with Lp(a) concentrations of 200, 700, 780,900, and 1200 mg/L by fractionating 0.5 mL of plasma by density-gradient ultracentrifugation (19) . Figure 3 shows the Lp(a) proffle in the individual with a Lp(a) concentration of 1200 mg/L, characterized by a maximal density of 1.075 kg/L. In the four other individuals studied, the density of the Lp(a) maximum ranged between 1.057 and 1.075 kgIL. The corresponding phenotypes of the glycoprotein were S3 for the subject with the lowest concentration and S2 for the others, in agreement with the predicted relationship between concentration and electrophoretic mobility (5) .
Comparison of the ELISA and RID assays. We assayed 38 samples from normal and hyperlipemic individuals both by ELISA 
Discussion
In this technique for quantification of human lipoprotein Lp(a), we used a combination of a monoclonal antibody against apo(a) to "capture" the antigen and a pelyclonal antibody against ape B, conjugated with peroxidase, for detection. This experimental procedure combines both the specificity of the monoclonal antibody and the stability and easy coupling procedure for the pelyclonal antibody. Moreover, it takes advantage of the nature of the Lp(a) particle, which is coupled to the antibody on the microtiter plate through its apo(a) moiety and is detected through its ape B content. This two-step ELISA assay is rapid, sensitive, specific, and simple to perform.
Previous studies (4, 6, 12) reported the plasma Lp(a) concentrations in normo-and hyperlipidemic subjects and in myocardial infarction survivors. Because of the high homology of Lp(a) with plasminogen, the values reported earlier with immunoassays involving pelyclonal antisera may have been overestimates (12) . For the Lp(a) assay, the use of a monoclonal antibody to apo(a) without crossreactivity with plasminogen (16) should ensure specificity.
Moreover, owing to the large concentration range observed within a normal population (<5 to >1500 mgIL) the Lp(a) assay must span a broader range than for the other apelipeproteins. In this respect, less-sensitive assays such as RID and enzyme iminunoassay do not fulfill the requirements for plasma Lp(a) measurements in a total population.
In patients undergoing coronarography, we have confirmed the observations of previous authors who reported that Lp(a) increases with the severity of the disease.
We monitored the Lp(a) concentrations in newborns, finding a significant increase in both Lp(a) and ape B between birth and the seventh postnatal day. The Lp(a) concentrations increased further up to eight months, whereas ape A-I and B concentrations remained constant. Our assay should also be suitable for use in screening newborns, because we could detect infants with abovenormal Lp(a) concentrations at seven days (21) .
This assay is therefore well suited for population studies as well as for the screening of individuals with high values for Lp(a), which may represent an additional risk factor for development of atherosclerosis and should therefore be detected at an early age.
